4.5 Article

Clinical effectiveness of bidirectional fecal microbiota transfer in the treatment of recurrent Clostridioides difficile infections

Journal

DIGESTIVE AND LIVER DISEASE
Volume 53, Issue 6, Pages 706-711

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2021.02.022

Keywords

Fecal microbiota transfer (FMT); Bidirectional FMT (bFMT); Clostridioides difficile infection (CDI); Stool transplant

Ask authors/readers for more resources

Simultaneous bidirectional FMT showed superior primary cure rates compared to standard unidirectional approaches for recurrent Clostridioides difficile infection, highlighting the importance of treatment route in optimizing patient outcomes. Further prospective studies are needed to confirm these findings.
Background: Fecal microbiota transfer (FMT) has become a standard of care in the prevention of multiple recurrent Clostridioides difficile (rCDI) infection. Aim: While primary cure rates range from 70-80% following a single treatment using monodirectional approaches, cure rates of combination treatment remain largely unknown. Methods: In a retrospective case-control study, outcomes following simultaneous bidirectional FMT (bFMT) with combined endoscopic application into the upper and lower gastrointestinal tract, compared to standard routes of application (endoscopy via upper or lower gastrointestinal tract and oral capsules; abbreviated UGIT, LGIT and CAP) on day 30 and 90 after FMT were assessed. Statistical matching partners were identified using number of recurrences ( < 3; >= 3), age and gender. Results: Primary cure rates at D30 and D90 for bFMT were 100% ( p = .001). The matched control groups showed cure rates of 81.3% for LGIT ( p = .010), 62.5% for UGIT ( p = .0 0 0) and 78.1% for CAP ( p = .005) on D30 and 81.3% for LGIT ( p = .010), 59.4% for UGIT ( p = .0 0 0) and 71.9% for CAP ( p = .001) on D90. Conclusion: In our analysis, bFMT on the same day significantly increased primary cure rate at D30 and D90. These data require prospective confirmation but suggest that route of application may play a signif-icant role in optimizing patient outcomes. ClinicalTrials.gov no: NCT026 8106 8 (c) 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available